The Six Best Abstracts

Giuliane, G.; Kubis, Caroline; Breukink, Stéphanie O.; Ferreira, Isabel; Lehur, Paul‐Antoine; Torre, Filippo La; Baeten, C.G.

doi:10.1111/codi.12704

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients have signed an informed consent form to participate in the study. The inclusion, exclusion criteria and initial results of the aforementioned prospective trial have been previously reported [38,39]. In short, patients under 80 years old with histologically confirmed stage II and III rectal cancer, located less than 15 cm from the anal verge, with no other cancer during the previous five years and normal cardiovascular, pulmonary, hepatic and renal functions, were included in the study.…”

Section: Study Population and Samplesmentioning

confidence: 99%

The Role of VEGFA, COX2, HUR and CUGBP2 in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients

et al. 2020

View full text Add to dashboard Cite

Background and objectives: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the aim of this study was to investigate the potential predictive value of VEGFA, COX2, HUR and CUGBP2 genes and the associations between post-treatment changes in gene expression and the efficacy of neoadjuvant therapy. Materials and Methods: Biopsies from RC and healthy rectal tissue of 28 RC patients were collected before neoadjuvant therapy and 6-8 weeks after neoadjuvant therapy. The expression levels of VEGFA, COX2, HUR, CUGBP2 genes were evaluated using a quantitative real-time polymerase chain reaction. Results: The results reveal a significantly higher expression of VEGFA, COX2 and HUR mRNA in RC tissue compared to healthy rectal tissue (p < 0.05), and elevated VEGFA gene expression in pre-treatment tissues was associated with a better response to neoadjuvant therapy based on T-stage downstaging (p < 0.05). The expression of VEGFA, HUR and CUGBP2 genes significantly decreased after neoadjuvant therapy (p < 0.05). Responders to treatment demonstrated a significantly stronger decrease of VEGFA and COX2 expression after neoadjuvant therapy than non-responders (p < 0.05). Conclusions: The findings of this study suggest that the pre-treatment VEGFA gene expression might have predictive value for the response to neoadjuvant therapy, while the post-treatment decrease in VEGFA and COX2 gene expression could indicate the effectiveness of neoadjuvant therapy in RC patients.

show abstract

Section: Study Population and Samplesmentioning

confidence: 99%